Biotechs Pressured Following Clinton Tweet (IBB)
Biotech stocks are getting hit on Monday following a post to Twitter by presidential candidate Hillary Clinton.
Clinton noted a New York times piece, which highlights a price increase in Daraprim from $13.50 up to $750 after Turing Pharmaceuticals acquired rights to the drug.
iShares Nasdaq Biotechnology (NYSE: IBB) is down 4.5 percent, Biogen (NASDAQ: BIIB) is down 5.2 percent, Allergan (NYSE: AGN) is down 2.9 percent, Gilead Sciences (NASDAQ: GILD) is down 2.6 percent, Amgen (NASDAQ: AMGN) is down 2.2 percent, Shire plc (NASDAQ: SHPG) is down 1 percent, among others.
The tweet is below:
Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on. -H https://t.co/9Z0Aw7aI6h
— Hillary Clinton (@HillaryClinton) September 21, 2015
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple (AAPL) announces 'Let Loose,' a special online event to be held in May
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Serve Robotics (SERV) Enters Production Agreement with Magna (MGA) to Scale Robot Manufacturing
Create E-mail Alert Related Categories
ETFs, Trader TalkRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!